ID: MRFR/MED/4884-HCR | | Region: Global | 85 pages
The legg-calve-Perthes disease treatment market is expected to register a significant growth during the forecast period (2018–2023).
Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.
Legg-calve-perthes disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the legg-calve-Perthes disease are often short compared to healthy individuals due to bone anomalies.
Major factors such as rising frequency rate in Perthes disease and increasing awareness about the Perthes disease boosts the market rate exponentially. Furthermore, the advancement of technology such as point-of-care drug delivery systems and focus on delivering good quality of life are some of the factors contributing to the growth of the market. Not identifying and treating the Perthes disease at initial stages are major restrains for the growth of the market.
The legg-calve-Perthes disease treatment market has been segmented on the basis of type, application, age group, and end-user.
On the basis of type, the Legg-Calve-Perthes Disease Treatment Market has been classified as non-surgical and surgical methods. The non-surgical method is segmented into anti-inflammatory medications, casting and bracing, crutches, and others. casting and bracing is further segmented into Newington brace, Toronto orthosis, Scottish rite orthosis, broomstick plasters, and Birmingham orthosis. The others segment is further segmented into conventional calipers, Snyder slings, slings with crutches, and traction. The surgical method is segmented into femoral osteotomy, innominate osteotomy, a combination of femoral osteotomy, and innominate osteotomy.
On the basis of application, the market has been classified as hip Fracture, hip dislocation, osteoarthritis, and congenital dysplasia of the hip.
On the basis of age group, the Legg-Calve-Perthes Disease Treatment Market has been classified as 4 to 6 years, 6 to 11 years, 12 to 19 years, and others.
On the basis of end-users, the Legg-Calve-Perthes Disease Treatment Market has been classified as hospitals, clinics, ambulatory surgical centers, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European legg-calve-Perthes disease treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The legg-calve-Perthes disease treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The legg-calve-Perthes disease treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
In the legg-calve-Perthes disease treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and also due to the rise in frequency of osteoarthritis.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to government funding and support from the healthcare sector coupled with increasing research and development.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.
The market in the Middle East and Africa is expected to account for the smallest share of the legg-calve-Perthes disease treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Some of the key players in the legg-calve-Perthes disease treatment market are BASF, Albemarle, Sunline, IOLCP, Shandong Xinhua Pharmaceutical Co. Ltd, Dr. Reddy's, DePuy Synthes, Prime Medical, Zimmer, Biomet Holdings, Inc., 3M Healthcare, Össur Hf, DJO, and Stryker Corporation.
Legg-Calve-Perthes Disease Treatment Market, by Type
Legg-Calve-Perthes Disease Treatment Market, by Application
Legg-Calve-Perthes Disease Treatment Market, by Age Group
Legg-Calve-Perthes Disease Treatment Market, by End-Users
Legg-Calve-Perthes Disease Treatment Implants Market, by Region
Frequently Asked Questions (FAQ) :
Lack of awareness can hold back Legg-Calve-Perthes Disease Market growth.
Legg-calve-perthes disease market report has ambulatory surgical centers, clinics, hospitals, and others.
The segments are osteoarthritis, hip dislocation, hip fracture, and congenital dysplasia of the hip in the legg-calve-perthes disease market report.
Legg-calve-perthes disease market report has North America has in charge.
Major players involved in legg-calve-perthes disease market are Albemarle, Sunline, BASF, Shandong Xinhua Pharmaceutical Co. Ltd, IOLCP, DJO, DePuy Synthes, Dr. Reddy's, Zimmer, Biomet Holdings, Inc., Prime Medical, Össur Hf, 3M Healthcare, and Stryker Corporation.